Evidence map›Paper›PMID 40500403›Full record

ArticleCellular & molecular immunology2025

Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.

Keke Huang, Yuqing Wu, Yu Kong, Qingyuan Xu, Mingwei Lv, Yirou Zhang, Yiteng Lu, Quanxiao Li, Cheng Li, Wenping Song and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Keke Huang *MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Yuqing Wu *Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China.
Yu KongMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Qingyuan XuDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Mingwei LvMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Yirou ZhangDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China.
Yiteng LuDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China.
Quanxiao LiMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Cheng LiMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Wenping SongMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaoyi ZhuMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Zhenlin YangDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Changchang XinDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China.
Xujiao ZhouDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China.
Tianlei YingMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. tlying@fudan.edu.cn.ORCID 0000-0002-9597-2843
Yanling WuMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. yanlingwu@fudan.edu.cn.
Jiaxu HongDepartment of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, Fudan University, Shanghai, China. jiaxu.hong@fdeent.org.ORCID 0000-0001-9912-633X

Funding

Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 23XD1400800
6 · The paper itself

Abstract

Addressing mucosal inflammatory disorders in the ocular surface or respiratory system remains a formidable challenge owing to the limited penetration of biological therapeutics across epithelial barriers. In this study, we explored the potential of human single-domain antibodies (UdAbs) as topical therapeutics for the targeted modulation of interleukin-33 (IL-33) in two mucosal-associated inflammatory disorders. The anti-IL-33 UdAb A12 demonstrated potent inhibition of the IL-33-mediated signaling pathway, despite not potently blocking the IL-33 receptor interaction. Compared with the anti-IL-33 control IgG itepekimab, the topical delivery of A12 resulted in significantly elevated corneal concentrations in vivo, which resulted in negligible ocular penetration. Moreover, A12 considerably ameliorated dry eye disease severity by exerting anti-inflammatory effects. Furthermore, in another murine model of allergic asthma, inhaled A12 substantially reduced overall lung inflammation. Our findings revealed the capacity of UdAbs to penetrate mucosal barriers following noninvasive localized delivery, highlighting their potential as an innovative therapeutic strategy for modulating mucosal inflammation.

Indexed as

AsthmaInflammationInterleukin-33Mucous MembraneSingle-Domain AntibodiesAdministration, TopicalAnimalsDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CSignal TransductionIL33 protein, humanInterleukin-33Single-Domain AntibodiesAsthmaDry eye diseaseHuman single-domain antibodyIL-33Mucosal InflammationTopical administration

Identifiers

PMID40500403
PMCPMC12311102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.